Better Buy: Biogen vs. Celgene [The Motley Fool]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: The Motley Fool
Better Buy: Biogen vs. Celgene Keith Speights ( TMFFishBiz Aug , 09 at :00PM Biogen NASDAQ:BIIB Celgene NASDAQ:CELG halting late-stage clinical studies for its once-promising Alzheimer's disease drug, aducanumab But with Celgene months away from being gobbled up Bristol-Myers Squibb NYSE:BMY Image source: Getty Images. Current products Biogen ascended to stardom in the biotech world on the strength of its multiple sclerosis (MS) franchise. This franchise includes blockbuster drugs Tecfidera, Tysabri, Avonex, and Plegridy. However, sales for interferon products Avonex and Plegridy are slipping. Growth for Tecfidera and Tysabri has also slowed down dramatically as new competitors have entered the market. The company's growth has been driven primarily by spinal muscular atrophy drug Spinraza, which Biogen licensed from Ionis Pharmaceuticals Novartis Biogen's three approved biosimilars Celgene's Revlimid generates over 0% of the company's total revenue. The blood cancer drug continues to
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Top Growth Stocks With Insider Backing In December 2024 [Yahoo! Finance]Yahoo! Finance
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- 3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income [Yahoo! Finance]Yahoo! Finance
- Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 10/31/24 - Beat
BMY
Sec Filings
- 12/13/24 - Form S-3ASR
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- BMY's page on the SEC website